Data Accountability Project

The Cure Clock

How much have we spent, how many times has the finish line moved, and where do we actually stand?

For more than half a century, medical researchers, pharmaceutical companies, and public institutions have promised cures for the conditions that cost the most lives and the most money. Billions of dollars have been committed. Timelines have been declared. And in many cases, those timelines have simply reset.

This page tracks ten major conditions across three dimensions: the money invested, the "breakthrough" claims made, and the actual proximity to a functional cure. The data speaks plainly. Where figures are estimates, they are labeled as such.

$0 Est. combined research spend (since 1970)
0 Documented "imminent cure" claims
0 Functional cures delivered
Scroll
Condition Tracker

Ten Conditions. Decades of Promises.

Each card tracks estimated cumulative research spending, the number of notable "imminent cure" declarations, and current proximity to a functional cure.

Stage 1: Basic Research
Stage 2: Mechanistic Understanding
Stage 3: Clinical Trials
Stage 4: Approved Partial Solution
Stage 5: Functional Cure
The Reset Counter
0
Documented "5-to-10 year" cure promises since 1980
Across all ten tracked conditions. Each represents a public declaration by a researcher, institution, or headline claiming a cure was imminent. The number resets. The clock does not.
Transparency

Methodology & Sources

Funding Data

Research spending estimates combine data from multiple sources. NIH categorical spending figures (2008-2024) are drawn from the NIH Research Portfolio Online Reporting Tools (RePORT) at report.nih.gov. Pre-2008 figures use NCI Budget Fact Books, NHLBI reports, and Congressional Research Service analyses. Figures include NIH funding, major nonprofit contributions (American Cancer Society, Michael J. Fox Foundation, JDRF, ALS Association), and estimated private-sector R&D where publicly reported.

  • NIH RePORT Categorical Spending: report.nih.gov/funding/categorical-spending
  • NCI Budget Fact Book: cancer.gov/about-nci/budget/fact-book
  • Congressional Research Service: NIH Funding FY1996-FY2025 (R43341)
  • American Heart Association Research Reports

All cumulative figures are inflation-adjusted to 2024 USD using BLS CPI data. Where exact historical breakdowns are unavailable, conservative estimates are used and labeled accordingly.

Promise Tracking

"Promise" counts represent documented instances of public declarations, typically by researchers, institutional leaders, or major news headlines, stating that a cure or breakthrough was "X years away." Counts are sourced from news archives (NYT, WSJ, Science, Nature), press releases from research institutions, and published retrospectives on research timelines.

These counts are conservative approximations. The actual number of such declarations is almost certainly higher, as many local or minor announcements are not tracked in major archives.

Proximity Stages

The five-stage proximity scale is an editorial framework, not a clinical classification. Stages reflect general consensus among researchers as of early 2026:

  • Stage 1: Basic Research — Fundamental mechanisms still being explored.
  • Stage 2: Mechanistic Understanding — Core biology understood, therapeutic targets identified, but no viable treatment pathway proven in humans.
  • Stage 3: Clinical Trials — Active human trials for curative (not just palliative) therapies.
  • Stage 4: Approved Partial Solution — FDA-approved treatments that manage or slow the condition but do not constitute a cure.
  • Stage 5: Functional Cure — A treatment that reliably eliminates or permanently controls the condition in most patients.
Limitations & Notes

This project is an editorial data visualization, not a peer-reviewed study. Key limitations:

  • Cumulative spending figures before 2008 rely on estimates and historical reports that may not capture all funding streams.
  • Private pharmaceutical R&D spending is proprietary and largely unreported by condition. Our figures undercount total investment.
  • "Cancer" encompasses hundreds of distinct diseases; spending and progress vary enormously by type. We track specific cancers where possible.
  • Promise counts are editorial judgments based on available documentation. Reasonable people may arrive at different counts.
  • Progress is nonlinear. A condition at Stage 3 today may reach Stage 5 faster than one that has been at Stage 4 for decades.